Avivagen, a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, thereby supporting general health and performance, is pleased to announce that it will be featured on an upcoming BioPub webcast hosted by Dr. KSS on Friday March 6th, 2020 at noon EST. The Company invites interested shareholders, investors, members of the media and the public to listen to and view the Company’s slide presentation.
BioPub has been analyzing small-cap special situation biotech investments for 7 years to readers in over 40 countries.
The webcast can be accessed free of charge as follows:
Or iPhone one-tap:
US: +16699009128,,687103833# or +16465588656,,687103833#
Dial(for higher quality, dial a number based on your current location):
US: +1 669 900 9128 or +1 646 558 8656
Webinar ID: 687 103 833
International numbers available: https://zoom.us/u/adDp8CXlOJ
BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don’t get and presence at meetings others don’t bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily. (taken from the BioPub website: www.biopubkss.com)
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, thereby supporting general health and performance By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture and OTCQB® Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock:
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Kym Anthony, CEO
Director of IR